U

Ultragenyx Tech Stack

Rare and ultrarare disease biopharmaceutical company with clinical-stage pipeline

Biotechnology Research Novato, California 1,001–5,000 employees Founded 2010 Public Company

Ultragenyx develops therapeutic medicines for rare genetic diseases with historically no approved treatments. The company operates across multiple late-stage programs (MPS VII, HOFH, LC-FAOD, GTX-102 for Angelman syndrome) with active commercialization and launch planning. Hiring velocity is accelerating across healthcare, sales, and engineering roles—a pattern typical of companies moving from clinical validation into multi-market deployment. Pain points cluster around new drug launches, commercialization execution, and regulatory manufacturing compliance, reflecting the operational complexity of bringing gene therapies to rare disease communities.

Tech Stack 10 technologies

Core StackServiceNow Cisco Meraki Azure Cisco ASA Excel Word PowerPoint

What Ultragenyx Is Building

◆Challenges

Commercializing rare disease therapy
New drug launch
Market development
Delivering innovative treatments
Launching new gene therapies
Evolving global hybrid network
Maintaining regulatory compliance in manufacturing
Lack of documentation
Improving training effectiveness
Reducing compliance risk

▲Active Projects

Mps vii treatment
Hofh treatment
Lc-faod treatment
Global medical strategy for dojolvi
Us launch of gtx 102 for angelman syndrome
Real-world evidence initiatives
Mps vii territory plan
Hofh territory plan
Lc-faod territory plan
North america brand strategy for gtx 102

Hiring Activity

Accelerating25 roles · 25 in 30d

Department

Healthcare

5

Sales

5

Engineering

4

Ops

4

Marketing

2

Research

2

Manufacturing

1

Operations

1

Seniority

Intern

9

Director

8

Senior

7

Mid

2

Notable leadership hires: Brand Lead, Medical Lead, Medical Director, Marketing Director

Company intelligence

Find more companies like Ultragenyx by tech stack, pain points and active projects

Get started free

About Ultragenyx

Ultragenyx Pharmaceutical develops transformative therapies for rare and ultrarare genetic diseases, many of which had no approved treatment options before the company's interventions. Founded in 2010 and headquartered in Novato, California, the company operates as a public pharmaceutical manufacturer with 1,001–5,000 employees. The organization spans research, clinical development, manufacturing, and commercial operations across the United States, Japan, Brazil, and Switzerland. Current focus areas include finalizing global medical strategy for approved programs, managing territory-level launch plans for multiple gene therapies, and building real-world evidence initiatives to support post-launch adoption and regulatory compliance.

HeadquartersNovato, California

Company Size1,001–5,000 employees

Founded2010

Hiring MarketsUnited States, Japan, Brazil, Switzerland

Frequently Asked Questions

What is Ultragenyx working on?

Four primary therapeutic programs: MPS VII treatment, HOFH treatment, LC-FAOD treatment, and GTX-102 for Angelman syndrome. Current projects include US launch planning, territory commercialization strategies, global medical strategy, and real-world evidence initiatives.